

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

19 Jun 2026

### Comparison of the effectiveness of carpal tunnel injection of corticosteroids and night splints, with daily splints in patients with carpal tunnel syndrome according to changes in the degree of symptoms based on assessment forms and electrodiagnostic study

#### Protocol summary

##### Study aim

Comparison of the effectiveness of local injection of corticosteroids and night splint with local injection of corticosteroids and day splints in patients with carpal tunnel syndrome.

##### Design

Clinical trial without control group, with parallel groups, double-blind, randomized, on 60 patients, It does not apply to phase. Permutation block method was used for randomization.

##### Settings and conduct

People will be divided into two treatment groups based on block randomization. In both groups, 40 mg methylprednisolone prednisolone was injected in an area slightly proximal to the distal fold of the wrist between the palmaris longus and flexor carpi radialis tendons at the volar level of the wrist. Then, in one group, a night splint will be prescribed, and in the other group, a daily splint will be prescribed. Also, for all patients, necessary training in the field of treatment process and activity and how to use The splint will be explained and also when the subjects enter the study and after 6 weeks, the symptom severity will be determined based on the VAS and Boston questionnaires, and the subjects will be subjected to electrodiagnosis and the relevant information will be recorded

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: 25-65 year olds with mild to moderate CTS. Exclusion : Diabetes melitus, pregnancy, hypothyroidism, rheumatoid arthritis, inflammatory arthritis, polyneuropathy, alcoholism, infections, cervical disc pathologies, history of trauma and surgery.

##### Intervention groups

Methylprednisolone injection in both study groups and then using wrist splint daily in one group and nightly in the other group for 6 weeks.

#### Main outcome variables

Changes in nerve conduction velocity ,median nerve latency , VAS and boston index and comparison between 2 groups after injection and use of night and day wrist splint.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20221020056249N1**

Registration date: **2022-12-11, 1401/09/20**

Registration timing: **registered\_while\_recruiting**

Last update: **2022-12-11, 1401/09/20**

Update count: **0**

##### Registration date

2022-12-11, 1401/09/20

##### Registrant information

##### Name

Forouzan Akbari

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 71 3230 5410

##### Email address

akbari.forouzan@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2022-12-04, 1401/09/13

**Expected recruitment end date**

2023-06-20, 1402/03/30

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Comparison of the effectiveness of carpal tunnel injection of corticosteroids and night splints, with daily splints in patients with carpal tunnel syndrome according to changes in the degree of symptoms based on assessment forms and electrodiagnostic study

**Public title**

Comparison of day and night splints in patients with CTS(carpal tunnel syndrome)

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

25-64 y/o Patients diagnosed with mild to moderate CTS in electrodiagnostic study.

**Exclusion criteria:**

Pregnancy Diabetes Melitus Hypothyroidism  
Inflammatory Arthropathy Rheumatoid Arthritis  
Polyneuropathy Alcoholism Infections Cervical disc pathologies History of past trauma or surgery

**Age**

From **25 years** old to **65 years** old

**Gender**

Both

**Phase**

N/A

**Groups that have been masked**

- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

**Sample size**

Target sample size: **60**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

The random allocation method in this study will be permutation block method. A represents a person who receives corticosteroid injections and daily splints, and B represents a person who receives corticosteroid injections and nightly splints. This method is based on blocks of four so that the total number of possible permutations of four is equal to 6: BAAB ABBA , BBAA ,AABB ,BABA ,ABAB Then, by using the table of random numbers and assigning a code from 0 to 9 to each of the permutations, the desired random list of 60 which includes 15 blocks of 4 is generated (using a computer) and the order of assigning each of the methods to Each of the samples participating in the study It is determined. In order to hide ,the random sequence method is used by another person who is unaware of the research process , and the questionnaires are completed by a person who is

unaware of the division of groups.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

Outcome assessor: Completed questionnaires and EDX findings are given to a person who is not aware of the interventions performed, and he is asked to rate the amount of pain reduction and increase in function and changes in nerve conduction velocity and latency according to the questionnaire and EDX findings. Data analyst: Finally, after completing and collecting all the information, the questionnaires are given to a person to check the information, who does not know about any of the work steps and how the intervention is divided.

**Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Shiraz University of Medical Sciences

**Street address**

The central building of Shiraz University of Medical Sciences, across the Felestin Ave., Zand Ave., Shiraz.

**City**

Shiraz

**Province**

Fars

**Postal code**

71348-14336

**Approval date**

2022-10-08, 1401/07/16

**Ethics committee reference number**

IR.SUMS.MED.REC.1401.343

**Health conditions studied****1****Description of health condition studied**

Carpal Tunnel Syndrome

**ICD-10 code**

G56.0

**ICD-10 code description**

Carpal tunnel syndrome

**Primary outcomes****1****Description**

VAS (visual analog scale) index for pain evaluation

**Timepoint**

At first and after 6 weeks of splint

**Method of measurement**

VAS questionnaire

**2**

**Description**

BCTSQ(Boston Carpal Tunnel Questionnaire) index for function evaluation

**Timepoint**

At first and after 6 weeks of splint

**Method of measurement**

Boston questionnaire

**3**

**Description**

NCV(nerve conduction velocity) and median nerve Latency in EDX( electrodiagnostic study)

**Timepoint**

At first and after 6 weeks of splint

**Method of measurement**

Electrodiagnostic study

**Secondary outcomes**

empty

**Intervention groups**

**1**

**Description**

Intervention group1: Injection of 40 mg of methylprednisolone is done in an area slightly proximal to the distal fold of the wrist between the palmaris longus and flexor carpi radialis tendons at the volar level of the wrist. Then a daily splint will be prescribed and also at the beginning of the study and after 6 weeks, the severity of symptoms will be determined based on the VAS and Boston questionnaires, and the subjects will be subjected to electrodiagnosis and the relevant information will be recorded.

**Category**

Treatment - Other

**2**

**Description**

Intervention group2: Injection of 40 mg of methylprednisolone is done in an area slightly proximal to the distal fold of the wrist between the palmaris longus and flexor carpi radialis tendons at the volar level of the wrist. Then a nightly splint will be prescribed and also at the beginning of the study and after 6 weeks, the severity of symptoms will be determined based on the VAS and Boston questionnaires, and the subjects will be subjected to electrodiagnosis and the relevant information will be recorded.

**Category**

Treatment - Other

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Shahid faghihi Hospital

**Full name of responsible person**

Forouzan Akbari

**Street address**

Next to medical university, Zand Ave., Shiraz.

**City**

Shiraz

**Province**

Fars

**Postal code**

۷۱۳۴۸۴۶۱۱۴

**Phone**

+98 71 3235 1087

**Email**

FaghihiHsp@Sums.ac.ir

**2**

**Recruitment center**

**Name of recruitment center**

Motahari Hospital

**Full name of responsible person**

Forouzan Akbari

**Street address**

Next to Namazi hospital, Namazi Sq., Shiraz.

**City**

Shiraz

**Province**

Fars

**Postal code**

۷۱۳۴۸۷۱۴۷۳۷

**Phone**

+98 71 3212 7001

**Email**

motahari@sums.ac.ir

**3**

**Recruitment center**

**Name of recruitment center**

Emam reza clinic

**Full name of responsible person**

Forouzan Akbari

**Street address**

Namazi Sq, Shiraz.

**City**

Shiraz

**Province**

Fars

**Postal code**

۷۱۳۴۸۷۱۴۷۳۷

**Phone**

+98 71 3612 1000

**Email**

emamreza@sums.ac.ir

#### 4

##### Recruitment center

**Name of recruitment center**

Emtiaz clinic

**Full name of responsible person**

Forouzan Akbari

**Street address**

Next to Chamran Hospital, Chamran Blvd.

**City**

Shiraz

**Province**

Fars

**Postal code**

7194815711

**Phone**

+98 71 3636 4001

**Email**

rajaeehospital@sums.ac.ir

#### 5

##### Recruitment center

**Name of recruitment center**

Hafez Clinic

**Full name of responsible person**

Forouzan Akbari

**Street address**

Abiverdi Blvd., Chamran Ave., Shiraz.

**City**

Shiraz

**Province**

Fars

**Postal code**

7194634786

**Phone**

+98 71 3647 9494

**Email**

Hafez@sums.ac.ir

## Sponsors / Funding sources

#### 1

##### Sponsor

**Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Mahtab Memar Poor

**Street address**

Main building of medical science, Zand St., Shiraz.

**City**

Shiraz

**Province**

Fars

**Postal code**

۷۱۳۳۶ - ۷۱۳۴۸

**Phone**

+98 71 3212 2430

**Email**

vcrdep@sums.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Shiraz University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

## Person responsible for general inquiries

##### Contact

**Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Forouzan Akbari

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Rehabilitation management

**Street address**

Shiraz Medical University of Science, Zand Ave., Shiraz Town.

**City**

Shiraz

**Province**

Fars

**Postal code**

7134814336

**Phone**

+98 71 3630 5123

**Email**

Akbari.forouzan@gmail.com

## Person responsible for scientific inquiries

##### Contact

**Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Forouzan Akbari

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Physical Medicine

**Street address**

Shiraz medical university, In front of Palestine St., Zand Ave., Shiraz Town.

**City**

Shiraz  
**Province**  
Fars  
**Postal code**  
7134814336  
**Phone**  
+98 71 3230 5410  
**Fax**  
**Email**  
akbari.forouzan@gmail.com

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Shiraz University of Medical Sciences  
**Full name of responsible person**  
Forouzan Akbari  
**Position**  
Resident  
**Latest degree**  
Medical doctor  
**Other areas of specialty/work**  
Physical Medicine  
**Street address**  
Shiraz medical university, In front of Palestine St.,  
Zand Ave., Shiraz Town.  
**City**  
Shiraz  
**Province**  
Fars  
**Postal code**  
7134814336  
**Phone**  
+98 71 3230 5410  
**Fax**  
**Email**

akbari.forouzan@gmail.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

### Study Protocol

Yes - There is a plan to make this available

### Statistical Analysis Plan

Yes - There is a plan to make this available

### Informed Consent Form

Yes - There is a plan to make this available

### Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

### Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

### Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

### Title and more details about the data/document

All collected deidentified IPD

### When the data will become available and for how long

Starting 6 months after publication

### To whom data/document is available

Academic institutions

### Under which criteria data/document could be used

Practitioners working in the same fields and who have CTS patients.

### From where data/document is obtainable

Shiraz medical science university

### What processes are involved for a request to access data/document

By making a request to the university

### Comments